Form D · Biotechnology
OraViz, Inc.
San Francisco, CA · CIK 0001635573
Offering snapshot reported Apr 8, 2015 · SEC filing
- Reported sold
- $103K Offering amount: $750K
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 19, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 8, 2015 | Initial | $103,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-237495
Source: Form D, filed Apr 8, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kelyn Brannon | Director |
| Thomas Gal | Director, Executive |
| Jeremy Horst | Director, Executive |
| Jason Horst | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2181 Greenwich Street
San Francisco, CA, 94123
San Francisco, CA, 94123